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The Pseudo-Leukocyte-Specific/Nuclear Membrane
Antinuclear Antibody Pattern: A Puzzle
Thomas K. Burnham, MB, BS* (London)
We report an antinuclear antibody (ANA) pattern—the
pseudo-leukocyte-specific/nuclear
membrane
(PLS/NM)
ANA pattern—that is puzzling because it usually reacts with
only a few cells on human spleen imprints but with most
epidermal and numerous dermal nuclei of normal human
skin sections. The designation
"pseudo-leukocyte-specific"
was chosen because it is generally seen in only a few nuclei
on human spleen imprints, thereby resembling the true
leukocyte-specific ANA pattern. A few small round nuclei

fluoresce homogeneously, surrounded by a bright wall,
suggesting nuclear membrane (NM) fluorescence. The term
"nuclear membrane" was added to the name because the
NM appearance is even more prominent on skin sections
where the pattern can be mistaken for the peripheral ANA
pattern of systemic lupus erythematosus (SLE). However, the
PLS/NM pattern has no clinical specificity, which makes it
essential to recognize it as separate from the pattern of
peripheral fluorescence.

For over 15 years, during which time we tested the sera
of approximately 38,000 patients (Table I), we have seen
a pattern of nuclear immunofluorescence that is puzzling
because it usually reacts with only a few cells on human
spleen imprints but with most epidermal and numerous
dermal nuclei of normal human skin sections. Because of
our uncertainty regarding the mechanism of this type of
nuclear immunofluorescence, we did not include it in our
previous descriptions and clinical correlations of the antinuclear antibody (ANA) immunofluorescent patterns (1-10).
However, since we see this pattern fairly frequently, we wish
to report it for the sake of completeness and in the hope that
this report might stimulate further research into the puzzle.

Materials and Methods
Clinical material
Sera of patients who had connective tissue diseases,
miscellaneous medical diseases, malignancies, and miscellaneous dermatoses were studied (Table I). Diagnoses were
based on characteristic clinical features and confirmatory
laboratory results.
Antinuclear antibody testing
The immunofluorescent spleen imprint technique was employed (1,2). This technique uses touch imprints of surgically
obtained human spleens as nuclear substrate for the indirect
fluorescent antibody technique. The spleens were initially
frozen in liquid nitrogen and stored at-76°C, Commercially
available fluorescein-conjugated goat antihuman gamma
globulin (Baltimore Biological Laboratories) was used (1),

The designation "pseudo-leukocyte-specific" (PLS) was
chosen because on human spleen imprints generally only
a few nuclei demonstrate this pattern, thereby resembling
the true leukocyte-specific antinuclear antibody pattern
(LSANA) (11,12). It is a nonparticulate pattern that, unlike
the particulate patterns (7), is not composed predominantly
of stained particles.

Sera were titrated undiluted 1:2, 1:5 and then diluted at
twofold dilutions in veronal buffered saline (pH 7,2 to 7,3).
The highest dilution producing an unequivocably positive
result followed by two consecutive negative dilutions was
considered to be the titration end point (1).

The morphology of this pattern is homogeneous, surrounded
by a bright wall, suggesting nuclear membrane involvement.
Because the nuclear membrane appearance is even more
prominent on skin sections, we added the term "nuclear
membrane" (NM) to the name. We report the morphology,
nuclear reactivity, and lack of clinical specificity of the
PLS/NM ANA pattern.
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Table i
Incidence and Titers of the PLS/NM A N A Pattern Since First
Recognized 1 1 / 1 / 6 9 Through 3 / 3 1 / 8 5

Number of patients tested

Total Patients
Tested for ANA

D O I II11-.

Blood
RA

SLE

DLF

Scleroderma

38,000

100

1,544

543

373

383

4 (1.07%)

3 (0.78%)

4 (1.07%)

3 (0.78%)

2-20 (5)

2-5 (5)

Number and percentage ( )
positive for PLS/NM
ANA without associated
other ANA pattern

236 (0.62%)

37 (2.4%)

Nuirtber and percentage ( )
positive for PLS/NM
ANA with and without
associated other ANA
pattern

273 (0.72%)

47 (3.0%)

Titer range and median
titer values I ) of patients
positive for PLS/NM ANA
without associated other
ANA pattern

U'-320

U-320 (20)

3* (0.55%)

*1 definite SLE, 2 probable SLE
' u = positive undiluted only

The slides were examined without cover slips with an
Ortholux II fluorescence microscope with a 95 X fluorite
oil-immersion objective with transmitted and incident light.
Other nuclear substrates
Selected sera demonstrating the PLS/NM ANA pattern were
tested on human spleen sections, human normal skin
sections, and human tonsil imprints, which were initially
frozen in liquid nitrogen. They were also tested on human
buffy coat peripheral blood smears (initially frozen and fresh)
and human Hep-2 cells (not frozen) (Table II).

Evaluation of different conjugates regarding comparative morphology and titers of the PLS/NM ANA pattern
Sera producing this pattern were tested on the human spleen
imprints with the anti-lgC and anti-Ca conjugates that were
used on the skin sections as well as with the antigamma
globulin conjugate normally used on the spleen imprints for
comparative morphology and evidence of C3 binding.
Simultaneous titrations of sera from ten patients in whom
this pattern was seen were performed on the spleen imprints
with the anti-lgC and antigamma globulin conjugates. The
same sera were titrated with the anti-lgC conjugate on the
skin sections within one to 16 days of the spleen titrations.
The comparative titrations were performed to ensure that
any differences or similarities in titers that might be found
on the skin sections vs the spleen imprints were not due to
the usual employment of the anti-lgC conjugate on the skins
and the antigamma globulin conjugate on the spleen
imprints.

All these substrates were tested with the antigamma globulin
conjugate except for the skin sections. The skin sections
were tested with fluorescein-labeled goat antihuman IgC
and anti-Ca with the conjugate characteristics and procedure
as previously described (13-17). Sera were titrated on the
skin sections with the anti-lgC conjugate. The sera were
tested undiluted, diluted 1:10, and then (sometimes) at
twofold but more usually at fourfold dilutions. Sera from 51
patients were titrated both on human spleen imprints with
the antigamma globulin conjugate and on the human skin
sections with the anti-lgC conjugate.

Blocking procedures
Blocking procedures using sera demonstrating this pattern
were performed on human spleen imprints and normal

Table II
Other Human Nuclear Substrates Tested w i t h Sera of Patients
w i t h the PLS/NM A N A Pattern on Human Spleen Imprints

Blood
Number of patients tested
and positive ( ) for
PLS/NM ANA

Skin

Smear

Tonsil

Hep-2 Cells

Spleen
Seclion

80 (80)

14 (0)

4 (4)

4 (0)

2 (2)
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human skin sections. Sera were diluted up to twofold
dilutions below their original titer and were incubated with
these two substrates followed by unlabeled antihuman IgC
and then the conjugated anti-lgC. Control slides were
incubated with bovine albumin after the serum incubation
instead of with the unlabeled antihuman IgC followed by
the conjugated anti-lgC. This represents a control incubation
with another protein solution instead of the unlabeled
antihuman IgG, Blocking could only be confirmed if the
slides incubated with the bovine albumin were positive while
those incubated with the unlabeled antihuman IgG were
negative.

were performed on sera from the same 40 patients tested
for single-stranded anti-DNA antibodies. A modification of
the technique of Nakamura et al (19) was employed.

Results
Clinical correlations
There have been no specific diagnostic correlations of this
pattern. The pattern may be seen in any of the connective
tissue diseases, with the highest incidence found associated
with rheumatoid arthritis. Conversely, no patients in whom
a diagnosis of systemic lupus erythematosus (SLE) was
confirmed demonstrated this nonparticulate pattern (7)
without an associated other ANA pattern (Table I), This is
consistent with our previous findings (20) that indicated that
patients who have SLE and other nonparticulate patterns (7),
such as the peripheral and homogeneous patterns, usually
have concomitant particulate patterns (showing stained
particles) (7,20). The only three patients with SLE who had
this pattern (Table I) had associated particulate patterns. One
of the two patients with probable SLE had only a questionable concomitant particulate pattern.

Antideoxyribonucleic acid tests
Tests for IgG antibodies to single-stranded deoxyribonucleic
acid (DNA) were performed on sera from 40 patients with
this pattern. A solid-phase radioimmunoassay (RIA) technique (18) was used.
Antiextractable nuclear antigen tests
Tests for antiextractable nuclear antigen (ENA) antibodies

Fig 1
Pseudo-leukocyte-specific/nuclear membrane (PLS/NM) antinuclear antibody (ANA) pattern on human spleen i m p r i n t . Scattered
small round nuclei are partially (arrow) and completely surrounded by a brightly fluorescent nuclear membrane-like wall. Scattered
brightly fluorescent, stippled components overlie the bodies (arrow) and walls (upper leff nucleus) of these nuclei. Original
magnification x 320.
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The PLS/NM ANA pattern was also seen in patients who
had malignancies and miscellaneous medical diseases including non-SLE renal diseases. It was found in three patients
who had poststreptococcal glomerulonephritis. However,
none of 100 blood donor control subjects showed this ANA
pattern. Positive results with the anti-Cs conjugate were also
sometimes seen, but again there was no association with any
specific disease.
No distinctive clinical characteristics were noted in the four
patients who had discoid lupus erythematosus (DLE) and the
three patients who had scleroderma in whom this ANA
pattern was the only pattern.
Titers (Table I) were relatively low (range: positive undiluted
only to 320); the majority of patients had titers of 40 or
lower. There was also no significant correlation between
titers and specific diagnoses, although the median titer was
20 in cases of rheumatoid arthritis, which was slightly higher
than in cases of DLE and scleroderma (where it was only
five). Titers of 40 were seen in patients who had ulcerative
colitis and poststreptococcal glomerulonephritis. One

ANA

patient who had mild alcoholic cirrhosis and degenerative
joint disease had a titer of 80,
PLS/NM ANA pattern on human spleen imprints
and spleen sections
This pattern was characterized on imprints by generally
involving only a few randomly distributed nuclei. The cells
appeared small and round, and the center of the nucleus
showed homogeneous fluorescence of various intensities
surrounded by a bright wall that sometimes showed a dark
center within it. Sometimes a few stippled structures were
seen overlying the walls and centers of the nuclei (Fig 1).
The appearance on human spleen sections was similar to
that on imprints in that again only randomly scattered
positive nuclei were seen. There was no tendency for
positive nuclei to be localized to any specific anatomic sites.
PLS/NM ANA pattern on other nuclear substrates
Human normal skin sections
The morphology differed slightly on the skin sections (Figs
2 and 3) (Table II) from that on the spleen imprints in that

Fig 2
PLS/NM A N A pattern on h u m a n normal skin
section. Most epidermal nuclei including those
of basal cell layer (right arrow) and f e w in dermis
(lower part of figure) show this pattern. Note
N M - l i k e , dark-centered walls that are separated
by w i d e gaps consisting of cytoplasm and intercellular spaces. Stippled components are seen
overlying some of these walls (arrows) including
one basal cell nucleus (right arrow). Original
magnification x 320.
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Fig 3
PLS/NM A N A pattern on human normal skin section. Several dermal nuclei show brightly fluorescent, dark-centered walls. Bright
stippled components overlie the walls (upper arrow) and centers of some nuclei. Note that some walls can be very broad (lower
a r r o w ) . Original magnification x 320.

the NM-like appearance was more prominent. There tended
to be less central homogeneous fluorescence possibly
because these were sections rather than imprints. The other
minor difference was that the stippled components overlying
both the nuclear walls and centers were seen more
frequently on the skin sections than on the spleen imprints.
The striking difference was one of numbers of positive nuclei
rather than morphology. The majority of epidermal nuclei
showed this pattern in all parts of the epidermis from the
basal cell layer to the granular layer. Numerous positive
nuclei were also seen in the dermis (Fig 3).

could be further differentiated both from peripheral ANA
and GEC by the presence of wider gaps between the
fluorescent walls. The gaps were composed of cytoplasm
and intercellular spaces (Fig 2), Also more fluorescent nuclei
were found in the dermis than are found with GEC.
Human tonsil imprints
These showed the pattern similarly to its appearance on the
human spleen imprints in that the positive nuclei tended to
be few in number and again were randomly distributed.

Despite the generally greater number of positive nuclei in
skin sections compared with the number in spleen imprints,
no significant differences were found between titers on the
skin sections and the spleen imprints of the 51 patients.

Human blood smears and Hep-2 cells
These substrates have not demonstrated this pattern. Both
initially frozen and fresh blood smears were negative.
However, we have only recently started to test Hep-2 cells
and have not had any strongly positive high-titered sera
available to evaluate.

The PLS/NM ANA pattern on skin had to be differentiated
both from peripheral ANA (Fig 4) and the general epidermal
cytoplasmic (GEO patterns (15-17), It differed from the
peripheral ANA pattern in that the fluorescent nuclear walls
tended to be broader than the usually thinner appearing
walls of the peripheral pattern. The PLS/NM ANA pattern

Comparative morphology and titers of PLS/NM ANA
pattern employing different conjugates
No morphologic differences were found with any of the
conjugates regarding this pattern. On spleen imprints, the
morphology was similar with the antihuman gamma
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Fig 4
Peripheral nuclear A N A pattern on human
n o r m a l skin section. Brightly fluorescent,
mainly contiguous, thin walls depict this pattern. It can be differentiated f r o m the PLS/NM
A N A pattern on skin sections by sparser and
narrower internuclear gaps and generally thinner fluorescent walls. A r r o w depicts dermalepidermal j u n c t i o n delineated by broad bandlike wall of peripheral nuclear fluorescence of
fhe lower parts of the basal cells. Original
magnification x 320.

globulin, anti-lgC, and anti-Ca, and also on the skin sections
no significant morphologic differences were found between
the anti-IgG and anti-Ca conjugates.
The comparative titrations of the ten patients' sera on the
spleen imprints with the antigamma globulin and the anti-IgG
conjugates and with the anti-IgG congugate on the skin
sections showed no significant differences. This finding
confirmed that the similar results from the 51 patients' sera
titrated on spleen imprints and skin sections with the
antigamma globulin and anti-IgG, respectively, were valid
and not due to the different conjugates employed.

positive for IgG antisingle-stranded DNA antibodies. One of
these three patients had bilateral uveitis. One of the two
remaining patients had gynecomastia and abdominal pain
of unknown origin; the other patient had a fever of unknown
origin and myalgias that might have been of psychogenic
origin. The specific diseases of the latter two patients were
not diagnosed.

Discussion
The PLS/NM ANA pattern remains puzzling. We have no
idea why the majority of epidermal nuclei show the pattern
while usually only a few nuclei demonstrate it on human
spleen imprints, and no blood smears show this pattern.

Blocking procedures
The PLS/NM ANA pattern was blocked both on human
spleen imprints and normal human skin sections,
respectively.

We thought that the antibody might be epidermal-nuclear
preferential, but the similar titers on skin and spleen do not
support this idea. Another possibility is that only nuclei in
a certain stage of cell division are reactive with this antibody,
but the reactivity of all the epidermal cells from the basal
layer upwards is against such an explanation. The finding
that the frozen blood smears were also negative rules out

Anti-DNA and anti-ENA results
None of the tests of 40 patients were positive for anti-DNA
or anti-ENA antibodies. Results in three patients were border
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the possibility that freezing is required to make the nuclei
reactive to this antibody, which was a possible reason for
the negative results on the unfrozen blood smears.
The lack of correlation with any specific disease is striking.
Patients who have SLE do not even show this pattern without
another associated ANA pattern. This is similar to our
findings regarding patients who have SLE with other nonparticulate patterns (20) as discussed above. The fact that none
of 100 blood donors demonstrated the pattern suggests that
this antibody—although nonspecific for any diagnosis—is
nevertheless produced in response to disease. The association ofthe pattern with poststreptococcal glomerulonephritis
further demonstrates the ubiquity of disease association of
this antibody.

Because of this lack of clinical significance, it is imperative
that this ANA pattern be recognized and separately classified. It is therefore essential not to confuse this pattern when
seen on human normal skin sections with the peripheral
ANA pattern, which confirms a clinical diagnosis of SLE
(1,2,9,21). The generally broader fluorescent nuclear walls
and more numerous and wider internuclear gaps, than are
seen with peripheral ANA, make this differentiation possible.
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